Do analysts prefer TXMD or XTLB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate XTLB or MRKR?

Marker Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 580.27%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts rate XTLB or VYNE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75

Does the media refer more to XTLB or VYNE?

In the previous week, XTL Biopharmaceuticals had 3 more articles in the media than VYNE Therapeutics. MarketBeat recorded 4 mentions for XTL Biopharmaceuticals and 1 mentions for VYNE Therapeutics. XTL Biopharmaceuticals' average media sentiment score of 0.97 beat VYNE Therapeutics' score of 0.94 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XTL Biopharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VYNE Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate XTLB or LPCN?

Lipocine has a consensus target price of $15.00, suggesting a potential upside of 527.62%. Given Lipocine's stronger consensus rating and higher probable upside, analysts plainly believe Lipocine is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Does the media favor XTLB or LPCN?

In the previous week, XTL Biopharmaceuticals had 3 more articles in the media than Lipocine. MarketBeat recorded 4 mentions for XTL Biopharmaceuticals and 1 mentions for Lipocine. XTL Biopharmaceuticals' average media sentiment score of 0.97 beat Lipocine's score of 0.39 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XTL Biopharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate NCEL or XTLB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, NCEL or XTLB?

XTL Biopharmaceuticals has higher revenue and earnings than NLS Pharmaceutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A XTL Biopharmaceuticals $450K 13.20 -$1.03M -$0.64 N/A

Is NCEL or XTLB more profitable?

Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A XTL Biopharmaceuticals N/A N/A N/A

Does the media refer more to NCEL or XTLB?

In the previous week, XTL Biopharmaceuticals had 3 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 4 mentions for XTL Biopharmaceuticals and 1 mentions for NLS Pharmaceutics. XTL Biopharmaceuticals' average media sentiment score of 0.97 beat NLS Pharmaceutics' score of 0.94 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive XTL Biopharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

XTL Biopharmaceuticals (XTLB) Competitors

$2.70 +0.21 (+8.43%)

Closing price 04:00 PM Eastern

Extended Trading

$2.65 -0.05 (-1.70%)

As of 07:48 PM Eastern

Compare

XTLB vs. TXMD, MRKR, VYNE, LPCN, and NCEL

Should you buy XTL Biopharmaceuticals stock or one of its competitors? MarketBeat compares XTL Biopharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with XTL Biopharmaceuticals include TherapeuticsMD (TXMD), Marker Therapeutics (MRKR), VYNE Therapeutics (VYNE), Lipocine (LPCN), and NLS Pharmaceutics (NCEL). These companies are all part of the "med - drugs" industry.

How does XTL Biopharmaceuticals compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

TherapeuticsMD has a net margin of 5.34% compared to XTL Biopharmaceuticals' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat XTL Biopharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
XTL Biopharmaceuticals	N/A	N/A	N/A

In the previous week, XTL Biopharmaceuticals had 4 more articles in the media than TherapeuticsMD. MarketBeat recorded 4 mentions for XTL Biopharmaceuticals and 0 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 1.89 beat XTL Biopharmaceuticals' score of 0.97 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Overall Sentiment
TherapeuticsMD	Very Positive
XTL Biopharmaceuticals	Positive

TherapeuticsMD has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

TherapeuticsMD has higher revenue and earnings than XTL Biopharmaceuticals. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	8.08	-$570K	$0.06	35.17
XTL Biopharmaceuticals	$450K	13.20	-$1.03M	-$0.64	N/A

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TherapeuticsMD beats XTL Biopharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Marker Therapeutics?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, XTL Biopharmaceuticals had 4 more articles in the media than Marker Therapeutics. MarketBeat recorded 4 mentions for XTL Biopharmaceuticals and 0 mentions for Marker Therapeutics. XTL Biopharmaceuticals' average media sentiment score of 0.97 beat Marker Therapeutics' score of 0.96 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
XTL Biopharmaceuticals	Positive
Marker Therapeutics	Positive

XTL Biopharmaceuticals has higher earnings, but lower revenue than Marker Therapeutics. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	13.20	-$1.03M	-$0.64	N/A
Marker Therapeutics	$3.55M	6.90	-$12.16M	-$0.61	N/A

Marker Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 580.27%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

XTL Biopharmaceuticals has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. XTL Biopharmaceuticals' return on equity of 0.00% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Marker Therapeutics	-343.03%	-73.29%	-59.70%

XTL Biopharmaceuticals has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

Summary

XTL Biopharmaceuticals beats Marker Therapeutics on 8 of the 15 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to VYNE Therapeutics?

XTL Biopharmaceuticals (NASDAQ:XTLB) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

XTL Biopharmaceuticals has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, indicating that its stock price is 100% more volatile than the broader market.

XTL Biopharmaceuticals has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. XTL Biopharmaceuticals' return on equity of 0.00% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

XTL Biopharmaceuticals has higher earnings, but lower revenue than VYNE Therapeutics. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	13.20	-$1.03M	-$0.64	N/A
VYNE Therapeutics	$454K	49.95	-$26.48M	-$0.38	N/A

In the previous week, XTL Biopharmaceuticals had 3 more articles in the media than VYNE Therapeutics. MarketBeat recorded 4 mentions for XTL Biopharmaceuticals and 1 mentions for VYNE Therapeutics. XTL Biopharmaceuticals' average media sentiment score of 0.97 beat VYNE Therapeutics' score of 0.94 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XTL Biopharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VYNE Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

XTL Biopharmaceuticals and VYNE Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Lipocine?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

XTL Biopharmaceuticals has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, Lipocine has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Comparatively, 6.4% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

XTL Biopharmaceuticals has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. XTL Biopharmaceuticals' return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Lipocine	-571.18%	-66.70%	-59.39%

Lipocine has a consensus target price of $15.00, suggesting a potential upside of 527.62%. Given Lipocine's stronger consensus rating and higher probable upside, analysts plainly believe Lipocine is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, XTL Biopharmaceuticals had 3 more articles in the media than Lipocine. MarketBeat recorded 4 mentions for XTL Biopharmaceuticals and 1 mentions for Lipocine. XTL Biopharmaceuticals' average media sentiment score of 0.97 beat Lipocine's score of 0.39 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XTL Biopharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

XTL Biopharmaceuticals has higher earnings, but lower revenue than Lipocine. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	13.20	-$1.03M	-$0.64	N/A
Lipocine	$1.98M	9.95	-$9.63M	-$1.88	N/A

Summary

XTL Biopharmaceuticals beats Lipocine on 10 of the 16 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NLS Pharmaceutics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

XTL Biopharmaceuticals has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
XTL Biopharmaceuticals	$450K	13.20	-$1.03M	-$0.64	N/A

In the previous week, XTL Biopharmaceuticals had 3 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 4 mentions for XTL Biopharmaceuticals and 1 mentions for NLS Pharmaceutics. XTL Biopharmaceuticals' average media sentiment score of 0.97 beat NLS Pharmaceutics' score of 0.94 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XTL Biopharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
XTL Biopharmaceuticals	N/A	N/A	N/A

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

XTL Biopharmaceuticals beats NLS Pharmaceutics on 7 of the 7 factors compared between the two stocks.

Get XTL Biopharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XTLB vs. The Competition

Export

Metric	XTL Biopharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.49M	$3.02B	$6.82B	$12.56B
Dividend Yield	N/A	2.02%	2.68%	6.64%
P/E Ratio	-4.22	20.06	27.94	24.55
Price / Sales	13.20	359.50	533.56	97.86
Price / Cash	N/A	57.28	48.59	58.15
Price / Book	1.09	4.32	10.91	6.45
Net Income	-$1.03M	$64.45M	$3.57B	$336.71M
7 Day Performance	5.06%	5.12%	3.62%	2.55%
1 Month Performance	17.90%	5.32%	4.40%	0.32%
1 Year Performance	N/A	30.23%	35.81%	25.76%

XTL Biopharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XTLB XTL Biopharmaceuticals	0.4419 of 5 stars	$2.70 +8.4%	N/A	N/A	$5.49M	$450K	N/A	N/A	News Coverage Gap Down
TXMD TherapeuticsMD	1.3112 of 5 stars	$2.01 +0.5%	N/A	+91.2%	$23.15M	$3.02M	33.50	420
MRKR Marker Therapeutics	2.4203 of 5 stars	$1.31 -4.4%	$10.00 +663.4%	-4.0%	$22.84M	$3.55M	N/A	60
VYNE VYNE Therapeutics	1.2372 of 5 stars	$0.65 +0.1%	N/A	-61.5%	$21.68M	$570K	N/A	30	News Coverage
LPCN Lipocine	3.6706 of 5 stars	$2.47 -2.4%	$15.00 +507.3%	-22.9%	$20.86M	$1.98M	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XTLB) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. TXMD, MRKR, VYNE, LPCN, and NCEL

How does XTL Biopharmaceuticals compare to TherapeuticsMD?

Summary

How does XTL Biopharmaceuticals compare to Marker Therapeutics?

Summary

How does XTL Biopharmaceuticals compare to VYNE Therapeutics?

Summary

How does XTL Biopharmaceuticals compare to Lipocine?

Summary

How does XTL Biopharmaceuticals compare to NLS Pharmaceutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB vs. The Competition

XTL Biopharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. TXMD, MRKR, VYNE, LPCN, and NCEL

How does XTL Biopharmaceuticals compare to TherapeuticsMD?

Is TXMD or XTLB more profitable?

Does the media favor TXMD or XTLB?

Which has more risk and volatility, TXMD or XTLB?

Which has stronger valuation and earnings, TXMD or XTLB?

Do insiders and institutionals believe in TXMD or XTLB?

Do analysts prefer TXMD or XTLB?

Summary

How does XTL Biopharmaceuticals compare to Marker Therapeutics?

Do institutionals and insiders believe in XTLB or MRKR?

Does the media favor XTLB or MRKR?

Which has higher earnings and valuation, XTLB or MRKR?

Do analysts rate XTLB or MRKR?

Is XTLB or MRKR more profitable?

Which has more risk & volatility, XTLB or MRKR?

Summary

How does XTL Biopharmaceuticals compare to VYNE Therapeutics?

Do analysts rate XTLB or VYNE?

Which has more risk and volatility, XTLB or VYNE?

Is XTLB or VYNE more profitable?

Which has stronger earnings & valuation, XTLB or VYNE?

Does the media refer more to XTLB or VYNE?

Do institutionals & insiders hold more shares of XTLB or VYNE?

Summary

How does XTL Biopharmaceuticals compare to Lipocine?

Which has more risk & volatility, XTLB or LPCN?

Do insiders & institutionals hold more shares of XTLB or LPCN?

Is XTLB or LPCN more profitable?

Do analysts rate XTLB or LPCN?

Does the media favor XTLB or LPCN?

Which has stronger valuation & earnings, XTLB or LPCN?

Summary

How does XTL Biopharmaceuticals compare to NLS Pharmaceutics?

Do analysts rate NCEL or XTLB?

Which has more risk and volatility, NCEL or XTLB?

Which has better valuation and earnings, NCEL or XTLB?

Does the media refer more to NCEL or XTLB?

Is NCEL or XTLB more profitable?

Do institutionals and insiders have more ownership in NCEL or XTLB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB vs. The Competition

XTL Biopharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools